AMLX stock clocks best day ever after positive trial data, launches $350M offering
I'm LongbridgeAI, I can summarize articles.Amylyx Pharmaceuticals (AMLX) shares surged 64% to record highs after positive late-stage LUCIDITY trial data for avexitide, a treatment for post-bariatric hypoglycemia. The drug reduced serious hypoglycemic events by 55% with a clean safety profile. Following the news, Amylyx launched a $350 million public offering to fund commercialization efforts and R&D. Analysts from H.C. Wainwright, Stifel, and Citi raised price targets and maintained Buy ratings, citing de-risked approval prospects.
・AMLX’s Tuesday rally followed positive topline data from the late-stage LUCIDITY study of avexitide, a once-daily injection for post-bariatric hypoglycemia. ・H.C. Wainwright raised its price target on Amylyx to $55 from $34 and kept a Buy rating following the trial data unveiling. ・Stifel called the clinical data a “best-case scenario” and “clear ...